Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222545 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
A Phase 2 study, sponsored by Omeros Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT02222545: Completed Phase 2 study, sponsored by Omeros Corporation.
NCT02222545 is a Phase 2 study that has completed, run by Omeros Corporation. The registered enrollment target is 58 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02222545, a Phase 2 study, has completed, sponsored by Omeros Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).
Primary Outcome
Incidence of treatment-emergent adverse events (AEs): clinically significant changes in vital signs, ECG, and laboratory tests were reported as AEs.
Interventions
- BIOLOGICAL OMS721
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2014-11-02 |
| Est. Completion | 2020-08-11 |
| Phase | Phase 2 |
What the finished NCT02222545 record still lists
NCT02222545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 1 intervention - of which OMS721 is the first listed.
NCT02222545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02222545 about?
NCT02222545 is a clinical study titled "Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies". The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).
What is the current status of trial NCT02222545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2014-11-02. Estimated completion is 2020-08-11.
What interventions are being tested in trial NCT02222545?
The interventions under investigation include: OMS721 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02222545?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02222545's enrollment target sits among peer trials
58 1135th of 2000 higher than 860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI